Bio-Path Holdings Reports 2nd Qtr 2012 Operational and Financial Results.

The article offers information on the 2012 2nd quarter financial performance of Bio-Path Holdings Inc. It informs that the company completed its Phase I clinical trial of BP-100-1.01 which may be used for systemic treatment for blood cancers including acute myeloid leukemia, chronic myelogenous leukemia and acute lymphoblastic leukemia. It further informs about net loss for the 2nd quarter 2012 which was 787,838 U.S. dollars.